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Abstract
Background A randomized trial of lobectomy versus segmentectomy for small-sized (≤ 20 mm) non-small cell lung cancer
(NSCLC) showed that patients who had undergone segmentectomy had a significantly longer overall survival (OS) than
those who had lobectomy. More attention is needed regarding the required extent of thoracic lymphadenectomy in patients
with small-sized NSCLC who undergo sublobar resection.
Methods The National Cancer Database was queried for patients with clinically node-negative NSCLC ≤ 20 mm who had
undergone sublobar resection between 2004 and 2017. OS of NSCLC patients by the number of lymph node dissections
(LNDs) was analyzed using log-rank tests and Cox proportional hazards model. The cutoff value of the LNDs was set to 10
according to the Commission on Cancer’s recommendation.
Results This study included 4379 segmentectomy and 23,138 wedge resection cases. The sequential improvement in the HRs
by the number of LNDs was evident, and the HR was the lowest if the number of LNDs exceeded 10. Patients with ≤ 9 LNDs
had a significantly shorter OS than those with ≥ 10 LNDs (hazard ratio [HR] 1.50, 95% confidence interval [CI] 1.40–1.61,
P < 0.0001). Multivariable analysis revealed that performing ≤ 9 LNDs was an independent factor for predicting OS (HR for
death: 1.34, 95% CI 1.24–1.44, P < 0.0001). These results remained significant in subgroup analyses by the type of sublobar
resection (segmentectomy, wedge resection).
Conclusions Performing ≥ 10 LNDs has a prognostic role in patients with small-sized NSCLC even if the resection is
sublobar.
Keywords Lung cancer · Surgery · Prognosis · Lung · Lymph node dissection
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of The Japanese Association for Thoracic Surgery (LOP4-2) and
recommended for submission.
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Lung cancer is the leading cause of cancer death [1]. The
majority of lung cancers are classified as non-small cell lung
cancer (NSCLC). Lobectomy has been the historical standard therapy for NSCLC patients with clinical IA disease.
For NSCLC patients who do not tolerate lobectomy, however, sublobar resection is one of the treatment options [2].
A recent Japanese phase III randomized trial of lobectomy
versus segmentectomy for small-sized (≤ 20 mm) peripheral
NSCLC showed that patients who had undergone segmentectomy had a significantly longer overall survival (OS) in
comparison with those who had lobectomy [3]. The number
of early-stage NSCLC patients who are indicated for sublobar resection is expected to increase, and thus more attention is warranted regarding the required extent of thoracic
lymphadenectomy in this population.
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In patients with early-stage NSCLC who undergo curative lung resection, the required extent of thoracic lymphadenectomy has been debated [4–8]. The American College of
Surgery Oncology Group (ACOSOG) Z0030 randomized
trial of complete systemic lymph node (LN) dissection vs.
mediastinal LN sampling revealed that complete removal
of the LNs via systemic LN dissection did not improve OS
in patients with early-stage NSCLC if systemic sampling of
the mediastinal and hilar LN was negative [4]. In contrast,
several previous studies reported that systemic LN dissection
provided a longer disease-free survival and OS than mediastinal LN sampling in patients with early-stage NSCLC [5, 6].
Based on the data of these previous studies, the Commission
on Cancer (CoC) recommends that at least ten LNs (hilar
and mediastinal LNs) should be pathologically examined
for resected early-stage NSCLC [9]. However, with regard
to patients with small-sized NSCLC who undergo sublobar
resection, the necessary extent of thoracic lymphadenectomy
has not been comprehensively investigated. The CoC and
National Comprehensive Cancer Network (NCCN) have
no recommendations for this. Thus, the aim of the current
study is to examine the prognostic significance of the number of LN dissections (LNDs) in patients with small-sized
(≤ 20 mm) NSCLC who undergo sublobar resection using
data from National Cancer Database (NCDB).

Materials and methods
NCDB
The NCDB is a joint project between the CoC of the American College of Surgeons and the American Cancer Society.
The CoC’s NCDB and the hospitals participating in the CoC
NCDB are the source of the de-identified data used herein;
they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by
the authors. The data are considered as hospital based rather
than population based. Based on the use of only de-identified
data, the study was exempted by the Parkview institutional
review board. The study flow diagram of case eligibility is
shown in Supplemental Fig. 1.

Statistical analysis
Kaplan–Meier curves by the number of LNDs were compared using the log-rank test. The number of LNDs was
analyzed according to two schemata. In the first schema,
they were classified into two groups (≥ 10, ≤ 9) according to
the CoC’s recommendation [9]. In the second schema, they
were classified into six groups (0, 1–2, 3–4, 5–6, 7–9, ≥ 10).
The associations between the number of LNDs and clinical demographics were assessed by Chi-square Fisher’s
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two-sided exact test. OS was defined as the time (months)
from diagnosis to death from any cause. Univariate and multivariable Cox proportional hazards analyses were performed
using JMP® 14.0 (SAS Institute Inc., Cary, NC, USA). A
two tailed, P < 0.05 was considered statistically significant.

Results
Patient characteristics
Patient characteristics (n = 27,517) are summarized in Supplemental Table 1. In total, 4379 (16%) and 23,138 (84%)
patients received segmentectomy and wedge resection,
respectively. Of the patients who had segmentectomy, 3557
(81%) and 822 (19%) of 4379 patients had ≤ 9 and ≥ 10
LNDs, respectively. In patients who underwent wedge
resection, 21,567 (93%) and 1571 (7%) of 23,138 patients
had ≤ 9 and ≥ 10 LNDs, respectively. Patients who had
segmentectomy were significantly associated with female
sex (P < 0.0001), academic institution (P < 0.0001), and
late years of diagnosis (P < 0.0001), tumor-bearing lobe
other than upper lobe (P < 0.0001), laterality other than
right (P < 0.0001), tumor size ≥ 10 mm (P < 0.0001), early
pathologic T stage (P < 0.0001), pathologic N1–2 stage
(P = 0.0003), negative resected margin status (P < 0.0001),
without or unknown status of adjuvant chemotherapy
(P = 0.0003), without or unknown status of adjuvant chest
radiation therapy (P < 0.0001), and ≤ 9 LNDs (P < 0.0001).
Regarding tumor size and pathologic T stage, the fact that
segmentectomy was associated with larger tumor size and
earlier pathologic T stage appears to be contradictory. This
may be because patients who had peripheral small tumors
tended to have wedge resection, and peripheral tumors can
more frequently have pleural invasion (T2) than centerlocated tumors. In addition, adjuvant chemotherapy or chest
radiation therapy was significantly more frequently performed in patients who underwent wedge resection than in
those who underwent segmentectomy. This may be because
wedge resection is associated with less number of patients
with negative resected margin status than those who had
segmentectomy, and those who had positive resected margin
status need adjuvant chemotherapy or chest radiation.

Relationship between clinical factors of patients
with small‑sized NSCLC and the number of the LNDs
by surgical procedures
The associations between clinical factors of patients
with small-sized NSCLC and the number of the LNDs
(≤ 9 vs. ≥ 10) according to the surgical procedures (segmentectomy vs. wedge resection) are shown in Table 1.
In patients who underwent sublobar resection, patients
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Fig. 1  The Kaplan–Meier curves of overall survival in patients with
small-sized (≤ 20 mm) non-small cell lung cancer who underwent a,
b sublobar resection, c, d segmentectomy, e, f wedge resection by the

number of lymph node dissections (a, c, e: ≥ 10 vs. ≤ 9, b, d, f: ≥ 10
vs. 7–9 vs. 5–6 vs. 3–4 vs. 1–2 vs. 0) are shown. LND; lymph node
dissection

with ≥ 10 LNDs were significantly associated with
younger age (P < 0.0001), other races (P = 0.0046),
academic institution (P < 0.0001), low Charlson–Deyo
score (P = 0.0006), late years of diagnosis (P < 0.0001),
larger tumor size (P < 0.0001), early pathologic T stage
(P < 0.0001), advanced pathologic N stage (P < 0.0001),
negative resected margin status (P < 0.0001), and without or unknown status of adjuvant chest radiation therapy (P < 0.0001). In patients who underwent segmentectomy, patients with ≥ 10 LNDs were significantly
associated with male sex (P = 0.0148), institution other
than academic (P < 0.0001), low Charlson–Deyo score
(P = 0.0366), late years of diagnosis (P < 0.0001), early
pathologic T stage (P = 0.0014), advanced pathologic N
stage (P = 0.0060), and negative resected margin status

(P = 0.0437). In patients who underwent wedge resection,
patients with ≥ 10 LNDs were significantly associated with
younger age (P < 0.0001), other races (P = 0.0011), academic institution (P < 0.0001), low Charlson–Deyo score
(P = 0.0127), late years of diagnosis (P < 0.0001), right
laterality (P < 0.0001), larger tumor size (P < 0.0001),
early pathologic T stage (P < 0.0001), advanced pathologic N stage (P < 0.0001), negative resected margin status (P < 0.0001), adjuvant chemotherapy (P = 0.0143), and
without or unknown status of adjuvant chest radiation therapy (P < 0.0001). The reasons why the LN dissection with
ten or more LNs was performed may be mainly because
such patients were young and the their Charlson–Deyo
score was low, indicating a promising long-term prognosis.
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Table 1  Clinical characteristics of patients with small-sized non-small cell lung cancer patients with ≥ 10 and those with ≤ 9 lymph nodes dissected according to the surgical procedures (n = 27,517)
Factors

Sublobar resection (n = 27,517)
Number of lymph nodes dissected
≤9
(n = 25,124)

Age
≥ 70
13,090 (52%)
< 70
12,034 (48%)
Sex
Male
10,210 (41%)
Female
14,914 (59%)
Race
Whites
22,544 (90%)
Others
2580 (10%)
Institution
Others
15036 (60%)
Academic
10088 (40%)
Charlson–Deyo score
≥2
4657 (19%)
0–1
20467 (81%)
Year of diagnosis
2004–2010
8431 (34%)
2011–2017
16,693 (66%)
Tumor-bearing lobe
Upper
15,967 (64%)
Others
9157 (36%)
Laterality
Right
13,261 (53%)
Others
11,863 (47%)
Tumor size
≥ 10 mm
21,276 (85%)
< 10 mm
3848 (15%)
Histology
Others
9605 (38%)
Adenocarci- 15,519 (62%)
noma
Pathologic T stage
T2–4
7202 (29%)
T1
17,922 (71%)
Pathologic N stage
N1–2
399 (2%)
N0
24,698 (98%)
Resected margin status
Other
1374 (5%)
Negative
23,750 (95%)
Adjuvant chemotherapy
Yes
1618 (6%)
No/unknown 23,506 (94%)
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Segmentectomy (n = 4379)
P value

≥ 10
(n = 2393)

Number of lymph nodes dissected
≤9
(n = 3557)

Wedge resection (n = 23,138)
P value

≥ 10
(n = 822)

Number of lymph nodes dissected
≤9
(n = 21,567)

P value

≥ 10
(n = 1571)

1124 (47%)
1269 (53%)

< 0.0001 1717 (48%)
1840 (52%)

405 (49%)
417 (51%)

0.6149

11,373 (53%)
10,194 (47%)

719 (46%)
852 (54%)

< 0.0001

1002 (42%)
1391 (58%)

0.2486

1304 (39%)
2253 (61%)

339 (41%)
483 (59%)

0.0148

8906 (38%)
12,661 (62%)

663 (42%)
908 (58%)

0.4903

2102 (88%)
291 (12%)

0.0046

3189 (90%)
368 (10%)

734 (89%)
88 (11%)

0.7516

19,355 (90%) 1368 (87%)
2212 (10%) 203 (13%)

0.0011

1305 (55%)
1088 (45%)

< 0.0001 2058 (61%)
1499 (39%)

551 (67%)
271 (33%)

< 0.0001

12,978 (60%)
8589 (40%)

< 0.0001

376 (16%)
2017 (84%)

0.0006

642 (18%)
2915 (82%)

123 (15%)
699 (85%)

0.0366

4015 (19%) 253 (16%)
17,552 (81%) 1318 (84%)

0.0127

578 (24%)
1815 (76%)

< 0.0001 1057 (30%)
2500 (70%)

155 (19%)
667 (81%)

< 0.0001

7374 (34%) 423 (27%)
14,193 (66%) 1148 (73%)

< 0.0001

1495 (62%)
898 (38%)

0.2965

2040 (57%)
1517 (43%)

455 (55%)
367 (45%)

0.3096

13,927 (65%) 1040 (66%)
7640 (35%) 531 (34%)

0.1989

1313 (55%)
1080 (45%)

0.0512

1665 (47%)
1892 (53%)

366 (45%)
456 (55%)

0.2445

11,596 (54%)
9971 (46%)

947 (60%)
624 (40%)

< 0.0001

2122 (89%)
271 (11%)

< 0.0001 3157 (89%)
400 (11%)

732 (89%)
90 (11%)

0.8540

18,119 (84%) 1390 (88%)
3448 (16%) 181 (12%)

< 0.0001

881 (37%)
1512 (63%)

0.1791

1334 (38%)
2223 (62%)

312 (38%)
510 (62%)

0.8107

8271 (38%) 569 (36%)
13,296 (62%) 1002 (64%)

0.0955

529 (22%)
1864 (78%)

< 0.0001

840 (24%)
2717 (76%)

152 (18%)
670 (82%)

0.0014

6362 (29%) 377 (24%)
15,205 (71%) 1194 (76%)

< 0.0001

127 (5%)
2266 (95%)

< 0.0001

85 (2%)
3472 (98%)

35 (4%)
787 (96%)

0.0060

314 (1%)
92 (6%)
21,226 (99%) 1479 (94%)

< 0.0001

69 (3%)
2324 (97%)

< 0.0001

106 (3%)
3451 (97%)

14 (2%)
808 (98%)

0.0437

1268 (6%)
55 (4%)
20,299 (94%) 1516 (96%)

< 0.0001

176 (7%)
2217 (93%)

0.0909

186 (5%)
3371 (95%)

46 (6%)
776 (94%)

0.0592

1432 (7%)
130 (8%)
20,135 (93%) 1441 (92%)

0.0143

754 (48%)
817 (52%)
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Table 1  (continued)
Factors

Sublobar resection (n = 27,517)
Number of lymph nodes dissected
≤9
(n = 25,124)

Segmentectomy (n = 4379)
P value

≥ 10
(n = 2393)

Adjuvant chest radiation
Yes
1713 (7%)
93 (4%)
No/unknown 23,411 (93%) 2300 (96%)

< 0.0001

Number of lymph nodes dissected
≤9
(n = 3557)

≥ 10
(n = 822)

132 (4%)
3425 (96%)

32 (4%)
790 (96%)

Univariate survival analyses in patients
with small‑sized NSCLC who underwent sublobar
resection according to the number of LNDs
The Kaplan–Meier curves comparing OS according to
the number of LNDs in patients with small-sized NSCLC
who underwent sublobar resection are shown in Fig. 1. As
shown in Fig. 1a, patients with ≤ 9 LNDs had a significantly
shorter OS than those with ≥ 10 LNDs (median OS: 89.4
vs. 120.2 months, hazard ratios [HR] for death: 1.50, 95%
confidence interval [CI] 1.40–1.61, P < 0.0001). The OS was
significantly influenced by the number of LNDs (Fig. 1b,
P < 0.0001). The subgroup analyses according to surgical
procedure (segmentectomy vs. wedge resection) were performed. In patients with small-sized NSCLC who underwent
segmentectomy, patients with ≤ 9 LNDs had a significantly
shorter OS than those with ≥ 10 LNDs (Fig. 1c, median OS:
90.0 vs. 102.8 months, HR for death 1.32, 95% CI 1.15–1.52,
P < 0.0001). The OS was significantly affected by the number of LNDs (Fig. 1d, P < 0.0001). Similarly, as shown in
Fig. 1e, patients with small-sized NSCLC who had wedge
resection and ≤ 9 LNDs had a significantly shorter OS than
those with ≥ 10 LNDs (median OS: 72.6 vs. 99.3 months,
HR for death: 1.47, 95% CI 1.35–1.60, P < 0.0001). The OS
was significant by the number of LNDs (Fig. 1f, P < 0.0001).
Figure 2a. summarizes the HRs for death by the number
of LNDs who underwent sublobar resection of small-sized
NSCLC. Sequential improvement in the HRs was observed,
and the HR was the lowest if the number of LNDs exceeded
10. These findings were similar in subgroup analyses according to the surgical procedures (segmentectomy; Fig. 2b,
wedge resection; Fig. 2c).

Univariate and multivariable analyses of OS
in small‑sized NSCLC patients who underwent
sublobar resection
The results of univariate and multivariable analyses for OS
in small-sized NSCLC patients who underwent sublobar
resection are shown in Table 2. Univariate analysis showed
that older age (P < 0.0001), male sex (P < 0.0001), white

Wedge resection (n = 23,138)
P value

Number of lymph nodes dissected
≤9
(n = 21,567)

0.8384

P value

≥ 10
(n = 1571)

1581 (7%)
61 (4%)
19,986 (93%) 1510 (96%)

< 0.0001

race (P < 0.0001), non-academic institution (P < 0.0001),
high Charlson–Deyo score (P < 0.0001), early year of
diagnosis (P < 0.0001), tumor-bearing lobe in upper lobe
(P = 0.0451), larger tumor size (P < 0.0001), wedge resection
(P < 0.0001), non-adenocarcinoma histology (P < 0.0001),
pathologic T2–4 stage (P < 0.0001), pathologic N1–2 stage
(P < 0.0001), positive/unknown status of resected margin
(P < 0.0001), adjuvant chemotherapy (P < 0.0001), and
nine or fewer number LNDs (HR for death: 1.50, 95% CI
1.40–1.61, P = 0.0115) were significantly associated with
worse OS. In multivariable analysis, older age (P < 0.0001),
male sex (P < 0.0001), white race (P = 0.0002), nonacademic institution (P < 0.0001), high Charlson–Deyo
score (P < 0.0001), early year of diagnosis (P = 0.0002),
tumor size in upper lobe (P < 0.0001), wedge resection
(P < 0.0001), non-adenocarcinoma histology (P < 0.0001),
pathologic T2–4 stage (P < 0.0001), pathologic N1–2 stage
(P < 0.0001), positive/unknown status of resected margin
(P < 0.0001), adjuvant chemotherapy (P = 0.0010), adjuvant chest radiation (P < 0.0001), and nine or fewer number
LNDs (HR for death: 1.34, 95% CI 1.24–1.44, P < 0.0001)
were independent factors for predicting OS. In subgroup
analyses of the patients who had segmentectomy and wedge
resection, nine or fewer number LNDs was an independent factor for predicting worse OS (HR for death 1.27,
95% CI 1.10–1.46, P = 0.0010 and HR for death 1.36, 95%
CI 1.25–1.49, P < 0.0001; Supplemental Tables 2 and 3,
respectively).

Discussion
The standard therapy for early-stage lung cancer is lobectomy and thoracic lymphadenectomy [10], and the CoC
recommends that at least ten LNs should be pathologically
examined for resected early-stage NSCLC [9]. However,
whether the recommendations can be applied to patients with
small-sized NSCLC who undergo sublobar resection had
been unclear. Given that a Japanese phase III randomized
trial of lobectomy versus segmentectomy for small-sized
(≤ 20 mm) peripheral NSCLC revealed that patients who
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Fig. 2  Hazard ratios for death by the number of lymph nodes evaluated who undergo a sublobar resection, b segmentectomy, and c wedge resection are shown. *P < 0.05; **P < 0.001

had undergone segmentectomy had a significantly longer OS
than those who had lobectomy [3], the required extent of thoracic lymphadenectomy in this population would be of interest to thoracic surgeons. In the current study, we showed the
prognostic and therapeutic significance for performing ≥ 10
LNDs in patients with small-sized (≤ 20 mm) NSCLC who
undergo sublobar resection. Regarding methodology of the
lymph node examination, the NCDB distinguishes lymph
node sampling from LNDs by code numbers. In this study,
LNDs data was used instead of lymph node sampling. Therefore, we recommend performing ≥ 10 LNDs. Moreover, the
subgroup analyses confirmed the survival benefit from ≥ 10
LNDs in both patients who had segmentectomy and those
who had wedge resection. The cutoff value of the number
of LNDs was determined with reference to CoC recommendations [9]. In addition, our analyses of the HRs for death
by the number of LNDs who underwent sublobar resection
also showed that the HR was the lowest when the number
of LNDs exceeded ten.
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The reason why patients with ≥ 10 LNDs had a significantly longer OS than those with fewer LNDs could be
explained by their therapeutic and diagnostic roles. Regarding the therapeutic role, more LNDs might contribute to the
removal of the potential metastatic LNs. In patients with
NSCLC ≤ 20 mm, the frequency of hilar and/or mediastinal
lymph node metastases has been reported to be 10–15% [11].
In addition, the ACOSOG Z0030 randomized trial showed
that “unexpected” LN metastases were observed in 4% of
patients who underwent systemic LN dissection [5]. As
shown in Table 1, our analyses of the clinical characteristics showed a significantly higher rate of pathological nodal
involvement in patients with ≥ 10 LNDs compared with
those with ≤ 9 LNDs, regardless of the surgical procedures
(segmentectomy, wedge resection). Sufficient dissecting of
LNs may eliminate microscopic nodal metastases, resulting in higher rate of remission. With regard to the diagnostic role, checking LNs in the middle of surgery may reveal
microscopic nodal involvement, leading to more accurate
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Table 2  Univariate and multivariable analyses of overall survival in
patients with small-sized non-small cell lung cancer ≤ 20 mm who
underwent sublobar resection (n = 27,517)
Factors

Age
≥ 70
< 70 (Ref)
Sex
Male
Female (Ref)
Race
Whites
Others (Ref)
Institution
Others
Academic (Ref)
Charlson–Deyo score
≥2
0–1 (Ref)
Year of diagnosis
2004–2010
2011–2017 (Ref)
Tumor-bearing lobe
Upper
Other (Ref)
Laterality
Others
Right (Ref)
Tumor size
≥ 10 mm
< 10 mm (Ref)
Surgical procedure
Wedge
Segmentectomy (Ref)
Histology
Others
Adenocarcinoma (Ref)
Pathologic T stage
T2–4
T1 (Ref)
Pathologic N stage
N1–2
N0 (Ref)
Resected margin status
Other
Negative (Ref)
Adjuvant chemotherapy
Yes
No/unknown (Ref)

Univariate

Multivariable

P value

P value

HR (95% CI)

Table 2  (continued)
Factors

HR (95% CI)

1.62 (1.57–1.68) 1.53 (1.48–1.59)
< 0.0001
< 0.0001
1.45 (1.40–1.50) 1.38 (1.33–1.42)
< 0.0001
< 0.0001
1.22 (1.15–1.29) 1.12 (1.05–1.19)
< 0.0001
0.0002
1.23 (1.19–1.28) 1.11 (1.07–1.15)
< 0.0001
< 0.0001
1.43 (1.38–1.49) 1.31 (1.26–1.37)
< 0.0001
< 0.0001
1.24 (1.19–1.29) 1.07 (1.03–1.12)
< 0.0001
0.0002
1.04 (1.00–1.08) 1.00 (0.96–1.04)
0.0451
0.9709
1.03 (0.99–1.07) 1.04 (0.99–1.07)
0.1006
0.0502
1.30 (1.24–1.37) 1.16 (1.10–1.23)
< 0.0001
< 0.0001
1.34 (1.28–1.41) 1.23 (1.17–1.30)
< 0.0001
< 0.0001
1.30 (1.26–1.35) 1.20 (1.16–1.25)
< 0.0001
< 0.0001
1.64 (1.58–1.70) 1.50 (1.44–1.55)
< 0.0001
< 0.0001
1.36 (1.21–1.53) 1.38 (1.21–1.56)
< 0.0001
< 0.0001
1.67 (1.56–1.79) 1.36 (1.27–1.46)
< 0.0001
< 0.0001
1.29 (1.21–1.37) 1.13 (1.05–1.21)
< 0.0001
0.0010

Univariate

Multivariable

P value

P value

HR (95% CI)

Adjuvant chest radiation
Yes
1.46 (1.37–1.55)
No/unknown (Ref)
0.8022
Number of lymph nodes dissected
≤9
1.50 (1.40–1.61)
≥ 10 (Ref)
0.0115

HR (95% CI)

1.22 (1.15–1.30)
< 0.0001
1.34 (1.24–1.44)
< 0.0001

Ref reference

staging. NCCN recommends chemotherapy for NSCLC
patients with pathological hilar LN metastasis (N1) and
chemotherapy for those with mediastinal LN metastasis
(N2) [2, 12]. Consistently, our analyses showed that patients
with ≥ 10 LNDs had a higher rate of adjuvant chemotherapy
than those with ≤ 9 LNDs. Thus, NSCLC patients with more
LNDs may be more accurately diagnosed and appropriately
assigned to receive adjuvant therapy or follow-up alone,
resulting in improved survival.
The multivariate analysis of OS showed that administration of adjuvant chemotherapy and/or chest radiation therapy
was associated with shorter OS. This may be because the
analyzed cohort included not only patients who were indicated for adjuvant therapy, but also those who were not. This
may also be because patients who were eligible for adjuvant
therapy but did not receive it were associated with higher
risks, such as interstitial pneumonia and older age.
Although clinical significance of lymph node dissection in
patients with resectable NSCLC has been well investigated,
previous studies have analyzed NSCLC patients with various sized tumors and those who had undergone lobectomy
or sublobar resection [4–8]. Based on the results from the
controlled randomized trial of lobectomy versus segmentectomy for small-sized NSCLC, the patients with NSCLC
within 20 mm should be recognized as a distinct population
who would benefit from segmentectomy [13, 14]. In that population specifically, survival benefit from lymph node dissection
has not been well clarified. A previous study investigating survival of patients with stage I NSCLC (< 20 mm) who undergo
sublobar resection using the Surveillance, Epidemiology, and
End Results database showed the similar results with our findings [15]. In that study, the number of LNDs was significantly
associated with survival after adjusting for several covariables,
although the authors did not analyze the comorbidity, which is
important in deciding the extent of LND, and the sample size
investigated (715 segmentectomy and 3201 wedge resection
cases) was much smaller than ours (4379 segmentectomy and
23,138 wedge resection cases) [15]. The authors did not set
the cutoff value of LNDs, but we adopted ten LNDs as the
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cutoff value according to the CoC’s recommendation. Thus,
our study elucidated that the CoC’s recommendation is applicable to patients with small-sized NSCLC even if the surgical
procedure is sublobar.
There are several limitations in association with our study.
First, this was a retrospective study in association with biases
from surgeon’s decision and/or patients’ statuses, including
age, comorbidities, and performance status. Our findings
should be validated in future studies with well-designed randomized trials. A Japanese randomized trial of lobe-specific
vs. systemic nodal dissection for clinical stage I-II NSCLC
(JCOG1413) may reveal whether the difference in the area of
LNDs influences the OS in patients with resected early-stage
NSCLC [7]. Second, the quality of data about the number of
LNDs is subject to the pathologists’ and surgeons’ assessment
of LNDs [16–19]. If pathologists fail to adequately investigate
LNs within the specimen, or surgeons removed some LNs in
fragments during lung cancer resections, NCDB can end up
identifying a lesser or greater number of total LNDs. These
factors influence the final available information regarding the
extent of LNs involvement, and these issues should be investigated in further studies with clearly-defined protocol parameters. Third, the stations of the LNDs were not available in the
NCDB databases. Not only the number of the LNDs, but also
their stations are associated with OS in patients with resected
NSCLC [20–22], which should be analyzed in future studies. Fourth, since the study analysis is based on the NCDB, it
is not possible to comprehensively collect several important
data including recurrence or cause of death for explaining the
oncologic effect regarding the number of LNDs.
In conclusion, our retrospective analysis investigating
a large sample size of patients with small-sized (≤ 20 mm)
NSCLC who underwent sublobar resection showed that ≥ 10
LNDs was an independent predictor of longer OS, suggesting the prognostic and therapeutic roles for performing ≥ 10
LNDs. Appropriate lymph node dissection is an important
issue in patients with small-sized NSCLC even if the resection is sublobar. Further research is warranted to validate these
findings.
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